Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

February 6, 2019

Bavencio Shows Promise in Heavily Treated Ovarian Cancer Patients in Phase 1b Trial

News

Immune checkpoint inhibitor Bavencio (avelumab) has an acceptable safety profile and shows some anti-tumor activity among heavily pretreated ovarian cancer patients, according to a Phase 1b trial. Findings from the trial were reported ... Read more

February 4, 2019February 6, 2019

Phase 1 Trial Testing IMV’s Tailored Immunotherapy Doses First Ovarian Cancer Patient

News

IMV’s Phase 1 clinical trial evaluating a personalized immunotherapy that targets mutated proteins called neoepitopes in ovarian cancer patients has started dosing participants, the company announced. “The first immunization of the ... Read more

January 30, 2019

Rubraca Maintenance Approved in Europe for Relapsed Ovarian Cancer

News

The European Commission has extended Rubraca‘s (rucaparib) approval as a maintenance therapy for women with advanced, relapsed ovarian cancer who are in complete or partial response to platinum-based chemotherapy. This recent ... Read more

January 25, 2019

Phase 3 Trial of Bavencio in Ovarian Cancer is Terminated

News

The immune checkpoint inhibitor Bavencio (avelumab) — given in combination and/or after platinum-based chemotherapy — is no better than chemotherapy alone at delaying disease progression or death in previously untreated women with ... Read more

January 18, 2019

Lynparza Improves Response Rate in Relapsed BRCA-mutated Advanced OC Patients

News

Results of a Phase 3 clinical trial show that Lynparza (olaparib) tablets met the primary goal of significantly improving the objective response rate, which is the percentage of patients whose cancer shrinks or ... Read more

January 2, 2019

AIVITA Doses First 10 Ovarian Cancer Patients with Cell-based Immunotherapy in Phase 2 Trial

News

The Phase 2 clinical trial evaluating AIVITA Biomedical’s cell-based immunotherapy for treating newly-diagnosed advanced ovarian cancer has dosed its first 10 patients. The study (NCT02033616) is looking to enroll 99 women at ... Read more

September 14, 2018

Celsion Doses First Ovarian Cancer Patient in Phase 1/2 Trial of GEN-1

News

The Phase 1/2 trial evaluating Celsion’s investigational DNA-based immunotherapy GEN-1 as an add-on to standard chemotherapy for localized treatment of ovarian cancer has started dosing patients. GEN-1 is a nanoparticle containing the DNA ... Read more

September 12, 2018

IMV’s Ovarian Cancer Trial Testing Triple Combo Therapy Doses First Patient

News

The Phase 1b/2 trial investigating IMV lead candidate DPX-Survivac in combination with Incyte‘s experimental epacadostat and low-dose chemotherapy in recurrent ovarian cancer patients has completed patient enrollment in the study’s first part, the ... Read more

August 29, 2018August 29, 2018

FDA OKs Phase 2 Trial Evaluating 2X-121 in Advanced Ovarian Cancer Patients

News

The U.S. Food and Drug Administration has green-lighted a Phase 2 clinical trial that will assess the safety and effectiveness of the small molecule 2X-121 in advanced ovarian cancer patients, Oncology Venture has ... Read more